Calling Cambridge, Massachusetts home, Fulcrum Therapeutics (NASDAQ: FULC ) is a clinical-stage biopharma focusing on the development of products for improving the lives of patients suffering from genetically defined diseases. In particular, it seeks to address conditions with high unmet medical needs. It features a small-molecule-based candidate that’s in Phase 3 trials for the treatment of muscular dystrophy. US FDA slaps new requirements for Indonesia's shrimp and spices after radioactive contamination Portfolio strategists recommend watching for January effect inflows that may push OTLK higher.
